Sessile serrated adenoma/polyps (SSA/Ps) of the colon account for 20-30% of all colon cancers.
| INTRODUCTION
Serrated colon polyps are commonly found during screening colonoscopy and are subdivided into hyperplastic polyps (HPs), sessile serrated adenoma/polyps (SSA/Ps), and traditional serrated adenomas. 1 Traditional serrated adenomas are rare while SSA/Ps and HPs are common. Unlike HPs, SSA/Ps may contribute up to a third of all colon cancers. [2] [3] [4] However, differentiating SSA/Ps from HPs is often difficult in clinical practice, and better markers of SSA/Ps are needed for accurate diagnosis and subsequent cancer prevention strategies. 5, 6 We have previously defined an RNA signature in SSA/Ps that distinguishes SSA/Ps from HPs and identifies a subtype of colon cancer likely to develop from SSA/Ps. 7, 8 The serrated polyposis syndrome (SPS) is an extreme phenotype that often presents with multiple serrated polyps and carries a high risk (up to 42%) of colon cancer development. [9] [10] [11] In clinical practice patients with SPS are routinely screened with annual colonoscopy, while patients with sporadic SSA/Ps are screened every 3 to 5 years.
Unlike familial adenomatous polyposis and Lynch syndrome, SPS lacks a known underlying genetic mutation. SPS is likely influenced by epigenetic mechanisms that do not require mutations in protein-coding genes. Increased methylation of gene promoters at CpG islands is observed in SSA/Ps and the underlying colon mucosa of SPS patients, suggesting that such methylation may contribute to altered gene expression in SSA/Ps. 2 However, it remains unknown what changes in RNA expression in SSA/Ps are required for progression to cancer.
MicroRNAs (miRNAs) are small non-coding RNAs of 18-24 nucleotides that regulate gene expression through mRNA degradation and translation inhibition. 12 A single miRNA may influence the expression of thousands of genes and multiple cellular processes necessary for the development of colon polyps and cancer. 13 MiRNA expression may also be regulated by DNA methylation. 14 Studies investigating miRNA-mRNA interactions in colon cancer cell lines have identified gene networks contributing to a malignant phenotype. 15 We have investigated miRNA expression by small RNA sequencing (RNA-seq)
in prospectively collected colon polyps and normal colon to identify gene networks important in the serrated pathway to colon cancer.
The few studies describing miRNA expression in serrated colon polyps have used microarray or reverse transcription quantitative PCR (RT-qPCR) with retrospectively collected formalin-fixed paraffinembedded (FFPE) tissue samples,, [16] [17] [18] rather than the much more comprehensive RNA-seq approach used in this study and presented for the first time. Also, no prior studies have examined mRNA targets of miRNAs differentially expressed in SSA/Ps. Our RNA sequencing analysis provides a more sensitive and complete analysis of miRNAs, including the discovery of unannotated, novel small RNAs. The goals of our study are threefold: First, define miRNA signatures for serrated polyp subtypes, SSA/Ps and HPs; second, compare serrated polypspecific miRNAs with colon cancer subtype miRNA profiles; and third, identify signaling pathways likely playing a role in SSA/P development.
We describe a unique miRNA profile in SSA/Ps that correlates with specific genomic aberrations and consensus molecular subtypes (CMSs) of colon cancer. We identify both growth factor and developmental signaling pathways in SSA/Ps that may drive progression to colon cancer. Ten SSA/Ps with matched uninvolved mucosa and two HPs without matched uninvolved mucosa were obtained from six patients with SPS. 7 SSA/Ps from five of these patients were previously analyzed by long mRNA sequencing. 8 Right colon was defined as the colonic region from splenic flexure to cecum. Left colon was defined as descending colon to rectum. Sporadic SSA/Ps (n = 6, five right colon, one left colon), HPs (n = 12, two right colon, ten left colon), and adenomatous polyps (APs, n = 14, ten right colon, four left colon) along with matched uninvolved mucosa (n = 26) were collected from screening colonoscopy patients. Normal colon tissue (n = 30, 15 right colon, 15 left colon) was obtained from patients with no polyps or other pathology found on current or prior exams. If polyps were found during colonoscopy, biopsies of polyp tissue were collected for both routine histopathological diagnosis and for storage in RNAlater as previously described. 7 All samples were collected prospectively and placed in RNAlater immediately after removal, stored at 4 C overnight and then at −80 C prior to performing RNA isolation. Samples were collected between years 2012 and 2018.
| MATERIALS AND METHODS

| Patients
| FFPE tissue samples
| Pathological classification
All biopsy specimens were reviewed by expert gastroenterology pathologists at the University of Utah. Serrated polyps were classified according to the recent recommendations of the Multi-Society Task
Force on Colorectal Cancer (CRC) for post-polypectomy surveillance and as described previously. 7, 8, 19 None of the SSA/Ps used in this study showed dysplasia.
| RNA isolation
Total RNA was isolated from colon biospecimens using TRIzol (Thermo 
| Serrated polyp and control colon comparisons
Normalization of small RNA-seq data from SSA/Ps (n = 16), HPs (n = 14), matched right uninvolved colon (n = 10), control right (n = 15), and control left colon (n = 15) was performed using the voom method as part of the limma package in Bioconductor. 23 Statistical differences in small RNA levels between SSA/Ps and HPs, uninvolved and control right colon, and control left and right colon were determined using the Lmfit and eBayes applications in limma. 24 2.7 | Sensitivity and specificity analysis of MIR31-5p
The sensitivity and specificity of MIR31-5p in differentiating SSA/Ps from HPs were determined using Receiver Operating Characteristic (ROC) statistics. The ROC curve was generated using the "roc" function in the "pROC" package of the R statistical computing language, version 3.2.1. The 95% confidence interval for the area under the curve (AUC) was estimated from 1000 bootstrap samples.
| qPCR validation of differentially expressed miRNAs
RT-qPCR was applied to 84 of the same 108 RNAlater-stored colorectal tissues that had been analyzed previously by small RNA-seq. These 
| Comparison to TCGA colon cancer RNAseq data
We compared our differentially expressed SSA/P miRNAs (FDR < 0.05, Supporting Information Tables S1 and S2) to small RNAseq colon cancer data publically available in the Cancer Genome Atlas (TCGA). 25 Two hundred and twelve TCGA colon cancers had both genomic aberration and CMS data available for our analysis. Of 32 differentially expressed miRNAs, only 24 could be evaluated in TCGA colon cancer data. Publically available TCGA small RNA-seq data were previously aligned to the Hg19 human reference genome and do not contain read data for seven recently identified miRNAs, or miRNAs with symbol numbers above 3000. Therefore, MIR3141, MIR3614, MIR3656, MIR3960, MIR4485, MIR4488, and MIR6089 were excluded from the analysis. MIR1299 was also excluded from the analysis because only 3 of 212 cancers had measurable read counts for this miRNA. The expression of 24 miRNAs (17 differentially expressed to paired uninvolved colon, 6 differentially expressed to HPs and 1 differentially expressed to both) was examined in 212 colon cancer small RNA-seq datasets. We compared the expression of each miRNA according to BRAF and KRAS mutation status, microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and CMS.
| Pathway analysis of putative mRNA targets
To predict mRNA targets for differentially expressed miRNAs we used the TargetScanHuman prediction tool within the Ingenuity miRNA target filter (Qiagen, Hilden, Germany) application. 26 TargetScan predicts biological targets by searching for conserved sites in mRNAs that match the seed region of each miRNA. After identifying putative mRNA targets for each miRNA, we used our previously obtained mRNA sequencing data 7 to filter for mRNAs with expression that was negatively correlated with miRNA expression. Canonical pathways were determined for all differentially expressed mRNAs (n = 5029) and mRNAs negatively correlated (n = 1390) with one or more miRNAs differentially expressed in SSA/Ps. 
| Differential gene expression analysis 3.2.1 | Polyp comparisons to paired uninvolved colon
Differentially expressed small RNAs in SSA/Ps, HPs, and adenomatous polyps (APs) were determined using paired DESeq2 negative binomial statistics as part of the online Oasis DE analysis module. 21 We com- We also compared 14 APs to paired uninvolved colon and identified 8 differentially expressed (Fold ≥ 1.5, FDR < 0.05) miRNAs and 1 piRNA (PIR012734) (Supporting Information Table S1 ). Three of the eight differentially expressed miRNAs in APs were also differentially expressed in SSA/Ps. The fold change and significance of the most differentially expressed miRNAs (Fold ≥ 2, FDR < 0.05) across the three polyp types are shown in Table 1 .
| Serrated polyp comparisons
Following voom normalization and lmfit and eBayes statistical analyses, we identified six miRNAs differentially expressed (Fold ≥ 1.5, FDR < 0.05) between 16 SSA/Ps and 14 HPs (Supporting Information   Table S2 ). Similar to comparisons to paired uninvolved colon, MIR31-5p was the most differentially expressed miRNA (11-fold, FDR < 0.05) in SSA/Ps compared to HPs (Figure 2 ). One other miRNA (MIR615-3p) was overexpressed and four miRNAs (MIR1247-5p, MIR204-5p, MIR210-3p, and MIR375) were underexpressed in SSA/Ps compared to HPs (Figure 2 ).
| Control colon comparisons
We Table S2 ).
| Sensitivity and specificity analysis of MIR31-5p
The sensitivity and specificity of MIR31-5p in differentiating SSA/Ps from HPs were determined using a ROC curve. The AUC for the accurate classification of serrated polyps ranged from 76.9% to 100%
(Supporting Information Figure S2 ).
| qPCR validation of differentially expressed miRNAs
RT-qPCR analysis of five target miRNAs (MIR31-5p, MIR21-3p, MIR378A-5p, MIR151A-3p, and MIR135B-5p) and one reference gene Table S4 ). Eight of twenty-four miRNAs (33%) were differentially expressed in CIMP cancers compared to cancers without CIMP (Table 2 ). Eight and three of twenty-four miRNAs were differentially expressed in BRAF-mutant or KRAS-mutant cancers compared to cancers without mutations in BRAF or KRAS, respectively (Table 2) . Five SSA/P-specific miRNAs, MIR9, MIR31, MIR615, MIR584, and MIR196B, were differentially expressed in both CIMPpositive and BRAF-mutant colon cancers.
We also investigated the expression of these 24 miRNAs in the recently described CMSs of colon cancer. 25 The same 212 TCGA colon cancer datasets were previously classified by CMS subtype (CMS1, n = 35; CMS2, n = 66; CMS3, n = 32; CMS4, 60; not classified, n = 19). Sixteen of twenty-four miRNAs differentially expressed in SSA/Ps were also differentially expressed (Fold ≥ 1.5, FDR < 0.05) in one or more of the 4 CMS subtypes. The majority of miRNAs (12/16 miRNAs, 75%) were differentially expressed in CMS1 compared to CMS2 colon cancers (Supporting Information Table S4 ). Eight of sixteen miRNAs (50%) were differentially expressed in CMS3 cancers, and nine of sixteen miRNAs (56%) were differentially expressed in CMS4 cancers (Supporting Information Table S4 ). The direction of fold change and overlap of each miRNA according to CMS subtype is shown in Figure 4A . All eight miRNAs differentially expressed in CMS3 cancers were also differentially expressed in CMS1 cancers. In contrast, only four of nine miRNAs differentially expressed in CMS4
cancers were also differentially expressed in CMS1 cancers. Hierarchical clustering of only these 10 miRNAs is shown in Figure 4B . The heatmap shows that BRAF mutation is also associated with the differential expression of these 10 miRNAs and suggests that these miRNAs may be used as a gene panel to identify CMS1 colon cancers with CIMP-H, MSI, and BRAF genomic aberrations.
| Pathway analysis of putative mRNA targets
Using the miRNA target filter application in Ingenuity Pathway Analysis (IPA) software, we compared our miRNA data with previously published messenger RNA data from SSA/Ps. 7 We identified 1390 mRNA targets with expression that was negatively correlated with one or more miRNAs differentially expressed in SSA/Ps. These 1390 mRNAs were further evaluated for canonical pathway enrichment, and the top 10 pathways are shown in Table 3 . Among the top pathways activated were ephrin receptor, insulin growth factor receptor, and ciliary neu- are very important. This study is the first to examine small RNA expression using RNA sequencing technology in prospectively collected serrated polyps. Small RNA profiles can be used to distinguish neoplastic from benign lesions. 27 We found many differentially expressed miRNAs in SSA/Ps that distinguish them from HPs including MIR31, MIR135B, MIR1247, and MIR204. The expression of MIR31 and MIR135B was further validated using RT-qPCR. We also describe for the first time the expression of SSA/P-specific miRNAs in colon cancer CMS 25 and the canonical pathways likely targeted by these miRNAs.
The expression of MIR31-5p was 26 to 129-fold higher by RT-qPCR in SSA/Ps compared to HPs and 45-fold higher compared to Expression of MIR31-5p, MIR21-3p, MIR378A-5p, MIR151A-3p, and MIR135B-5p by reverse transcription quantitative PCR analysis. Expression of each miRNA was normalized to MIRLET7G-5p expression and fold change (y axis) determined relative to the mean of control colon values. Individual sample values and the mean AE SE for each of seven sample groups (x axis) are shown. "AP" denotes adenomatous polyp and "unin" denotes uninvolved colon. The number of samples analyzed in each group is shown in parentheses. Statistical significance was calculated using the Mann-Whitney U-test. ns denotes not significant has also been detected in serum of patients with CRC 34 and is more highly expressed in MSI-H CRCs. 35 Recent studies have shown increased MIR31 expression in SSA/Ps suggesting MIR31 plays a role in the serrated pathway to colon cancer. 16, 36 A study by Nosho and colleagues 16 showed a positive association of MIR31 expression with BRAF mutation and poor colon cancer prognosis.
To our knowledge, our study is the first to show overexpression of MIR135B in SSA/Ps. MIR135B expression is frequently elevated in colon cancer. 30 Dysregulation of MIR135B has been associated with APC dysfunction that may lead to the development of hereditary or sporadic colon cancers. 37, 38 MIR135B promotes tumor proliferation, progression, and invasion. 38 Increased MIR135B levels are found in the stools of patients with colorectal adenomas when compared to patients with normal colon mucosa. 39 In one study, higher MIR135B expression in tumor tissue also correlated with improved disease-free and cancer-specific survival (time until tumor related death) in patients with rectal cancer. 40 Increased MIR21 expression occurs in CRC and correlates with overall reduced survival and unfavorable prognosis. 41, 42 Schmitz and colleagues 43 showed increased expression of MIR21 in both SSA/Ps and HPs. Evidence suggests it plays a role in cell proliferation and invasion in CRC by targeting the PTEN gene. 44 Our qPCR validation of SSA/P-specific miRNA expression showed that MIR21 was elevated (1.5-fold) in SSA/Ps but was not statistically significant.
Other miRNAs differentially expressed in SSA/Ps in our study were MIR584, MIR3614-5p, and MIR378A-3p. MIR584 expression has not been previously reported in serrated polyps or serrated carcinoma.
MIR3614-5p is highly expressed in cervical tumor samples and distinguishes them from normal tissue. 45 No data on MIR3614-5p expression are available in colon cancer tissue or polyps. Our study is the first to show increased expression of MIR3614-5p in SSA/Ps. MIR378A-3p was significantly downregulated in SSA/Ps compared to paired uninvolved colon. Similar downregulation of MIR378 was found in CRC by microarray and RT-qPCR. 46, 47 Decreased expression of MIR378 was also observed in KRAS-mutant colon cancers. 48 Evaluation of SSA/P-specific miRNA expression in TCGA colon cancer datasets identified many miRNAs that are differentially expressed in CIMP positive colon cancers compared to CIMP negative cancers ( Table 2 ). The expression of MIR9, MIR31, MIR196B, MIR584, and MIR615 is highly correlated with CIMP tumor status and BRAF mutation. These changes in expression were most prominent in CIMP high (H) compared to CIMP low (L) colon cancers. However, MIR9 and MIR31 show changes in both CIMP-H and CpG island methylator phenotype-low (CIMP-L) colon cancers, suggesting a gradation in expression of these miRNAs according to the level of CpG island methylation. MIR31 and MIR584 were also differentially expressed in KRASmutated cancers, which further supports the idea that KRAS mutations are genetic events that contribute to the serrated neoplasia pathway.
MIR9 has been reported to function in CRC as a tumor suppressor by suppressing cell migration and decreasing tumor proliferation. 32, 49 Decreased expression of MIR9 has been noted in colon adenomas compared to normal colon. 47 Our small RNA-seq data show similarly downregulated MIR9 in adenomas (Fold < −1.8, FDR < 0.003). MIR9 expression has been associated with colon cancer patient survival. 50 Methylation of the MIR9 promoter frequently occurs in colon cancer and is associated with lymph node metastasis. 51 The expression of MIR196B and MIR615 is also highly correlated with MSI tumors, suggesting that these miRNAs are associated with colon cancers that develop through the serrated pathway. These findings are in agreement with two previous studies comparing miRNA expression in MSI and stable colon cancers. 52, 53 MIR196 has been implicated in a variety of gastrointestinal cancers, and its upregulation was noted in CRC. 54 It has also been detected in plasma of patients with colon cancer. 54 Our analysis of MIR196B suggests that reduced expression is associated with SSA/Ps and CIMP-positive, MSI colon cancers. Increased expression of MIR615-3p has been documented in poorly differentiated and more proximal colon cancer. 55 It should be noted that MIR615 is more highly expressed in proximal than distal colon, and therefore differences in MIR615 expression among colon cancer subtypes may reflect differences in tumor location.
SSA/P-specific miRNA expression also overlapped with one or more colon cancer CMSs, most notably CMS1 ( Figure 4A,B) . CMS1
colon cancers have been previously described as CIMP-positive, microsatellite-unstable, and BRAF-mutated. 25 MIR31, MIR196B, and MIR615 expression is highly correlated with CMS1 cancers and each of these genomic aberrations. These three miRNAs were also differentially expressed in CMS3 and CMS4 cancers, suggesting that the serrated neoplasia pathway overlaps with other cancer subtypes.
The CMS3 subtype of colon cancer is characterized by a CIMP-L pattern of DNA methylation and frequent mutations in KRAS. 25 These genomic aberrations have been considered part of an alternative serrated pathway to cancer, although the precursor lesions that harbor these changes are not well defined. 56 Interestingly, this alternative serrated pathway to cancer may account for the majority of serrated colon cancers and include up to 20% of all colon cancers. 56 In contrast, only 15% of colon cancers are believed to develop from the classic serrated pathway that includes BRAF mutation, CIMP-H DNA methylation, and MSI though silencing of MLH1.
MIR31 is overexpressed in CMS1, CMS3, and CMS4 colon cancers compared to CMS2 cancers (Supporting Information Table S4 ). In fact, all eight miRNAs differentially expressed in CMS3 cancers were also differentially expressed in the same direction in CMS1 colon cancers, suggesting significant molecular overlap between these two cancer subtypes. MIR31, MIR135B, and MIR584 were overexpressed in both BRAF-mutated and KRAS-mutated colon cancers, also suggesting molecular overlap between CMS1 and CMS3 subtypes. MIR31 showed increased expression in CIMP-L cancers, also consistent with the CMS3 subtype.
CMS4 subtype colon cancers are characterized by activation of transforming growth factor beta (TGFB) signaling and upregulation of genes involved in epithelial-to-mesenchymal transition (EMT). 25 These cancers have high levels of somatic copy number alterations, are MSS and have infrequent CIMP DNA methylation. 25 The majority of miRNAs (8 of 11, 73%), including MIR135B, are underexpressed in CMS4 colon cancers compared to CMS2 cancers. When compared to the mean expression of all other CMS subtypes (CMS1, CMS2, and CMS3), MIR31 and MIR584 are also underexpressed in CMS4 cancers ( Figure 4B ). These data suggest that the miRNA profile in CMS1 colon cancers is more similar to CMS3 than CMS4 cancers.
The canonical signaling pathways affected in SSA/Ps are consistent with enhanced growth factor signaling (Table 3) . Ephrin receptor and insulin-like growth factor 1 signaling are increased while PPARα and PTEN signaling are decreased, each suggesting enhanced phosphoinositide 3 kinase (PI3K) signaling in SSA/Ps. Concomitant
Pten and Kras mutations in mice increase cell proliferation along the crypt-villus axis, branching of intestinal villi and the formation of HPs and sessile serrated adenomas. 57 Sessile serrated adenomas from these mice also show increased levels of phosphorylated AKT, ERK, and MEK protein, suggesting increased PI3K signaling. 57 Colon cancers with PI3KCA exon 20 or PTEN mutations are associated with a proximal location, BRAF mutation, MSI and are CIMP-H, 58 suggesting that these cancers develop through the sessile serrated pathway. Similarly, PIK3CA exon 9 mutations are also common in proximal colon cancers but are associated with a CIMP-L phenotype and KRAS mutation, 58 suggesting an alternative serrated pathway to colon cancer. These findings are consistent with the miRNA profiles and signaling pathways we have found altered in SSA/Ps. However, mutations in PIK3CA and PTEN have not been described in SSA/Ps, which warrants further research in this area.
TGFB signaling, also increased in SSA/Ps, primarily induces EMT in BRAF-mutated colon organoids but not organoids derived from traditional adenomas. 59 It has been hypothesized that CMS4 subtype colon cancers may develop from SSA/Ps due to common gene signatures in Each of the 1390 mRNAs are targets of one or more SSA/P-specific miRNAs as determined by HumanTargetScan. P-values represent the hypergeometric test of enrichment based on the number of genes differentially expressed in the pathway compared to the total number of genes in the pathway. z score represents whether the pathway is activated (>2.0) or inhibited (<−2.0) based on the direction of fold change for each differentially expressed gene in that pathway.
